Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

German Biopharmaceutical Partners to Seek Osteoarthritis Drug

By BiotechDaily International staff writers
Posted on 02 Dec 2013
Two German biopharmaceutical companies are joining forces to develop a new class of drugs for treatment of osteoarthritis.

At the present time there are no truly effective treatments for osteoarthritis of the knee, which, according to the World Health Organization, effects more than 5% of adults over the age of 40 (more than 30 million people) in the developed countries.

To boost the search for drugs to treat osteoarthritis, Biopharm GmbH (Heidelberg, Germany) and Merck Serono (Darmstadt, Germany) have agreed to embark on a two-year joint discovery program focused on a potential pro-anabolic osteoarthritis modifying drug based on a growth factor derived from Biopharm's growth factor platform technology.

According to the terms of the agreement, Biopharm will provide variants of a wild type protein, which is thought to drive hyaline joint cartilage formation during embryogenesis and seems to be associated with osteoarthritis, as well as early preclinical research services. In the event of identification of potential development candidates, Merck Serono will own exclusive development and commercialization rights.

“We have insight that the maternal protein shows an important role in joint cartilage formation. These findings raise hope that a modified wild type protein may induce cartilage regeneration in the osteoarthritic joint,” said Dr. Frank Plöger, CSO of Biopharm. “The alliance will draw on the combined expertise and resources of Merck Serono and Biopharm with the ultimate goal to develop a disease modifying osteoarthritis drug. Although we have knowledge about the molecule, we need a partner like Merck Serono, who does not only provide the necessary resources, but also know how best to set up of our research program to ensure a successful hand over to clinical experts.”

Related Links:

Biopharm GmbH
Merck Serono



Channels

Genomics/Proteomics

view channel
Image: Typical antibodies (left) unfold in the harsh environment of the cell. Camelid antibodies (right) are smaller and more stable (Photo courtesy of the Washington University School of Medicine).

Double Targeting Approach Increases Potential for Cancer Treatment with Oncolytic Viruses

Cancer researchers have used a double targeting approach to direct oncolytic viruses specifically to tumor cells where they reproduce until the cancer cells burst, releasing more viruses to infect and... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.